MLAB Mesa Laboratories Dashboard

Mesa Laboratories, Inc. engages in the design, manufacture, and marketing of instruments and disposable products utilized in healthcare, pharmaceutical, food, and beverage, medical device, and petrochemical industries. It operates through the following segments: Sterilization and Disinfection, Instruments, Cold Chain Monitoring, and Cold Chain Packaging. The Sterilization and Disinfection segment offers testing services, along with the manufacturing and marketing of biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization and disinfection processes in the hospital, dental, medical device, and pharmaceutical industries. The Instrument segment manufactures and markets control instruments and disposable products. The Cold Chain Monitoring segment designs, develops, and markets systems which are used to monitor environmental parameters such as temperature, humidity, and differential pressure. The Cold Chain Packaging segment provides consulting services including compliance monitoring, packaging development, and validation or mapping of transport and storage containers, and thermal packaging products. The company was founded by Luke R. Schmieder on March 26, 1982 and is headquartered in Lakewood, CO.

Company profile

Ticker

MLAB

Exchange

NASDAQ

Website

mesalabs.com

CEO

Gary Owens

Incorporated

Colorado

Location

Colorado

Fiscal year end

Mar 31

Sector

Manufacturing > Instruments and Related Products Manufacturing for Measuring, Displaying, and Controlling Industrial Process Variables

Industry (SIC)

Industrial Instruments For Measurement, Display, and Control

Fortive • Roper • Ametek • Sensata Technologies Holding • Keysight • Danaher • MKS Instruments • Cognex • Rudolph • Hurco Companies ...

Former names

MESA LABORATORIES INC /CO

SEC CIK

0000724004

Corporate docs

Articles of Incorporation & Bylaws

IRS number

840872291

MLAB stock data

S&P 500

1M 1Y 2Y 5Y

News

Pro users get this 30m faster

Mesa Laboratories Q3 EPS $1.46 Up From $0.65 YoY, Sales $34.17M Up From $31.66M YoY

3 Feb 21

Mesa Laboratories (NASDAQ:MLAB) reported quarterly earnings of $1.46 per share. This is a 124.62 percent increase over earnings of $0.65 per share from the same period last year. The company reported $34.17 million in

Press releases

Pro users get this 30m faster

MESA LABS DECLARES QUARTERLY DIVIDEND

5 Apr 21

LAKEWOOD, Colo., April 05, 2021 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, "Mesa Labs" or the "Company") today announced that its Board of Directors has declared a regular quarterly

Mesa Labs Reports Third Quarter Results for FY21

3 Feb 21

LAKEWOOD, Colo., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) today announced results for the third quarter ("3Q21") and nine months ended December 31, 2020. Financial highlights

Calendar

3 Feb 21

17 Apr 21

31 Mar 22

Financial summary

Financial statements Chart MLAB financial data

Quarter (USD)	Dec 20	Sep 20	Jun 20	Mar 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Mar 20	Mar 19	Mar 18	Mar 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated)	Burn method: Change in cash		Burn method: Operating income/loss		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	253.73M	253.73M	253.73M	253.73M	253.73M	253.73M
Cash burn (monthly)	(positive/no burn)	(positive/no burn)	1.91M	(positive/no burn)	(positive/no burn)	(positive/no burn)
Cash used (since last report)	n/a	n/a	6.82M	n/a	n/a	n/a
Cash remaining	n/a	n/a	246.91M	n/a	n/a	n/a
Runway (months of cash)	n/a	n/a	129.3	n/a	n/a	n/a

Beta Read what these cash burn values mean

Recent insider trades

MLAB insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
5 Apr 21	Sullivan John James	Common Stock	Sell	Dispose S	No	Yes	250.76	500	125.38K	57,458
5 Apr 21	Sullivan John James	Common Stock	Sell	Dispose S	No	Yes	250.76	500	125.38K	33,894
26 Mar 21	Sullivan John James	Common Stock	Gift	Aquire G	Yes	No	0	23,564	0	23,564
26 Mar 21	Sullivan John James	Common Stock	Gift	Dispose G	No	No	0	23,564	0	34,394
16 Mar 21	Guillemin Evan	Common Stock	Sell	Dispose S	No	Yes	269.48	720	194.03K	32,035
12 Mar 21	Sakys John	Common Stock	Sell	Dispose S	No	No	263.84	2,500	659.6K	4,350
12 Mar 21	Sakys John	Common Stock	Option exercise	Aquire M	No	No	70.56	2,000	141.12K	6,850
12 Mar 21	Sakys John	Common Stock	Option exercise	Aquire M	No	No	48.72	500	24.36K	4,850
12 Mar 21	Sakys John	Non Qualified Stock Option Common Stock		Dispose X	No	No	70.56	2,000	141.12K	32,496
12 Mar 21	Sakys John	Non Qualified Stock Option Common Stock		Dispose X	No	No	48.72	500	24.36K	34,496

Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q4 2020

MLAB institutional ownership history Ownership history

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

91.5% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	171	149	+14.8%
Opened positions	26	7	+271.4%
Closed positions	4	23	-82.6%
Increased positions	58	82	-29.3%
Reduced positions	59	34	+73.5%

13F shares	Current	Prev Q	Change
Total value	1.73B	1.21B	+42.7%
Total shares	4.7M	4.76M	-1.4%
Total puts	0	0
Total calls	0	0
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
BLK Blackrock	776.23K	$222.5M	+3.5%
Conestoga Capital Advisors	504.64K	$144.65M	+1.1%
Royce & Associates	307.25K	$88.07M	-1.0%
Vanguard	305.79K	$87.65M	+1.5%
IVZ Invesco	265.82K	$76.2M	-3.6%
TROW T. Rowe Price	261.3K	$74.9M	-15.2%
STT State Street	174.87K	$50.13M	+1.4%
Kayne Anderson Rudnick Investment Management	169.89K	$48.7M	+0.9%
Ranger Investment Management	164.48K	$47.15M	-5.0%
Artisan Partners Limited Partnership	130.89K	$37.52M	+2.3%

Largest transactions	Shares	Bought/sold	Change
GS Goldman Sachs	12.3K	-64.5K	-84.0%
TROW T. Rowe Price	261.3K	-46.78K	-15.2%
Renaissance Technologies	14.1K	-28K	-66.5%
BLK Blackrock	776.23K	+26.26K	+3.5%
Glenmede Trust Co Na	26.7K	+17.87K	+202.4%
JPM JPMorgan Chase & Co.	18.91K	+17.14K	+970.6%
Dimensional Fund Advisors	4.64K	-16.56K	-78.1%
R.P. Boggs & Co. Wealth Mangement	15.23K	+15.23K	NEW
Schroder Investment Management	109.03K	+13.05K	+13.6%
ATAC Neuberger Berman	1.69K	-12.89K	-88.4%

Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Thermo Fisher Scientific • STERIS Plc (Ireland) • Amphenol • STERIS Plc (Ireland) • Fortive • Steris

Management Discussion

Our results of operations and period-over-period change are discussed in the following section. The tables and discussion below should be read in conjunction with the accompanying Consolidated Financial Statements and the notes thereto appearing in Item 8. Financial Statements and Supplementary Data (in thousands, except percent data).

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: AcquiredWe, Butler, capacity, comparison, depleted, Docment, examination, exceeded, expansion, experienced, fall, inconsistent, indemnified, invoiced, IRS, Jersey, jurisdiction, loosening, obsolete, preacquisition, produced, progressed, properly, reaction, recover, remit, remitted, remitting, resume, resumed, roll, subsidiary, summer, technical, tightening, unrealized, USD, vaccine, viability, weakened, weakening